araag2/HINT huggingface dataset:
Clinical trial NCT02338245 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: aslan001, lapatinib, capecitabine
SMILES: C[C@@H]1COC(NC2=CC=C3N=CN=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)C3=C2)=N1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented histological confirmation of breast cancer with HER 2
             overexpression or gene amplification prior to study entry.

          -  Patients with HER 2-positive metastatic breast cancer that have failed on prior first
             line treatment with trastuzumab or who have progressed within 1 year of treatment with
             trastuzumab in adjuvant setting.

          -  Presence of at least one radiographically measurable disease (bone metastases and
             ascites are not considered measurable lesions).

          -  Patients of the respective country's legal age or older at the time of written
             informed consent.

          -  Patients with acceptable organ and hematological function

        Exclusion Criteria:

          -  Patients with radiation treatment or major surgical procedures within 21 days prior to
             study entry.

          -  Patients with malabsorption syndrome, diseases significantly affecting
             gastrointestinal function, resection of the stomach or small bowel, or difficulty in
             swallowing and retaining oral medications.

          -  Patients with an uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes,
             hypertension, or psychiatric illness/social situations that would limit compliance
             with study requirements.

          -  Patients with any history of other malignancy unless in remission for more than 1
             year. (Nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with
             curative intent is not exclusionary).

          -  Patients with symptomatic central nervous system metastasis and/or on systemic
             steroids or anticonvulsants within 3 months before the first dose of randomized
             therapy.

          -  Patients who are pregnant or breast-feeding.

          -  Patients who were previously treated with ASLAN001 and/or with lapatinib.

          -  Patients who have received more than 2 lines of any therapies in metastatic stage.

          -  Patients who have received any investigational drug (or have used an investigational
             device) within 21 days or received any antineoplastic monoclonal antibodies within a
             period of 5 half-lives before receiving the first dose of randomized therapy.

          -  Patients with unresolved or unstable serious toxicity from prior administration of
             another investigational drug and/or prior cancer treatment.
Clinical trial NCT02342977 (phase 2, status: withdrawn)
Conditions: osteoarthritis, rheumatoid arthritis, avascular necrosis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, I77.5, K04.1, N64.1, J85.0, K76.2, M87.050, K85.01
Drugs: placebo, lacosamide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Reason stopped: 
    we were unable to enroll any patients into the study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be eligible for participation if they are 18-70 years of age.

          -  Patients who have an American Society of Anesthesiologists physical status I-III.

          -  Patients who are scheduled for primary total hip arthroplasty.

          -  Any patients who are willing to comply with study requirements and agrees to be in the
             study.

        Exclusion Criteria:

          -  A patient's refusal to participate.

          -  Inability to give consent.

          -  Any patients on a scheduled opioid regimen for pain greater than 3 months.

          -  Bleeding diathesis.

          -  Hypersensitivity to lacosamide or any component of the formulation (some formulation
             contains phenylalanine) and/or any drug allergies to any medications used in this
             study.

          -  Second- or third-degree atrioventricular (AV) block, sick sinus syndrome without
             pacemaker, sodium channelopathies (e.g., Brugada syndrome), myocardial ischemia, heart
             failure, and structural heart disease.

          -  Severe hepatic and or renal impairment.

          -  Pregnant or can become pregnant.

          -  Breast-Feeding.

          -  Have any suicidal thoughts, depression, or behavioral changes.

          -  Taking any antiepileptic medications.

          -  Any known seizure disorder (e.g. Lennox-Gastaut syndrome).

          -  Currently prescribed:

        Carbamazepine Strong inhibitors of cytochrome P450-2C9 (Capecitabine; Delavirdine;
        floxuridine; Fluorouracil (Systemic); Gemfibrozil; Nicardipine; Sitaxentan; Sulfadiazine;
        Sulfissoxazole; Tegafur; Tolbutamide) Strong inhibitors of cytochrome P450-3A4 (Atazanavir;
        Boceprevir; Chloramphenicol; Clarithromycin; Cobicistat; Conivaptan; Darunavir;
        Delavirdine; Fosamprenavir; Indinavir; Itraconazole; Ketoconazole (Systemic); Lopinavir;
        Nefazodone; Nelfinavir; Nicardipine; Posaconazole; Ritonavir; Saquinavir; Telaprevir;
        Telithromycin; Voriconazole) Delavirdine Fosphenytoin Nicardipin Phenobarbital Phenytoin
        Ethinylestradiol
Clinical trial NCT02343445 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: p-1037, hypertonic saline, saline
SMILES: [Na+].[Cl-], COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 12 years of age or older.

          -  Diagnosis of cystic fibrosis as determined by the 1997 CF Consensus criteria (NIH
             Consensus Statement, 1997)

          -  Non-smoker

          -  FEV1 at Screening Visit 1 between 40% and 90%

          -  Stable regimen of CF medications and chest physiotherapy for the 28 days prior to
             Screening. Must be willing to discontinue use of hypertonic saline for the duration of
             the study.

          -  Clinically stable for at least 2 weeks

          -  All females of child-bearing potential must have a negative serum pregnancy test and
             if sexually active must agree to practice a highly effective form of contraception
             throughout the study and for 28 days after the last dose of study medication.

        Exclusion Criteria:

          -  History of any organ transplantation or any significant disease or disorder

          -  Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs or
             trimethoprim in the 28 days prior to Screening

          -  History of significant intolerance to inhaled hypertonic saline, as determined by the
             Investigator

          -  Known hypersensitivity to the study drug or amiloride

          -  Any clinically significant laboratory abnormalities at Screening Visit 1 as judged by
             the investigator, or any of the following:

               -  Potassium ≥ 5 milliequivalent per Liter (mEq/L)

               -  Abnormal renal function

               -  Abnormal liver function, defined as ≥ 3 x upper limit of normal (ULN)

               -  Hemoglobin level < 10.0 g/dL

          -  Female who is pregnant or lactating

          -  History of sputum or throat swab culture yielding Burkholderia species or
             Mycobacterium abscessus within 2 years of screening

          -  Has previously participated in an investigational trial involving administration of
             any investigational compound or use of an investigational device with 28 days prior to
             Screening

          -  Currently being treated with any ivacaftor containing regimen
Clinical trial NCT02344550 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: everolimus(afinitor), letrozole, leuprolide(lorelin depot)
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 20 years

          -  Histologically or cytologically confirmed, HER-2 negative breast cancer with recurrent
             or metastatic disease

          -  No HER2 overexpressing breast cancer

          -  Premenopausal status, defined as either

          -  ER and/or PR positive

          -  Progressive disease on tamoxifen treatment or sequential or combined treatment of
             tamoxifen and GnRH agonist as a palliative or an adjuvant endocrine treatment

          -  Duration of tamoxifen treatment should be at least 3 months or more

          -  No prior treatment with an aromatase inhibitor or inactivator or fulvestrant, or mTOR
             inhibitors

          -  One line of chemotherapy in metastatic setting is permitted

          -  ECOG performance status 0,1 or 2

          -  At least one measurable lesion or mainly lytic bone lesions in the absence of
             measurable disease

          -  Adequate hematologic, liver and kidney function

        Exclusion Criteria:

          -  Pregnant women or patients in lactation

          -  More than one line of prior chemotherapy for metastatic breast cancer

          -  GnRH agonist with tamoxifen treatment within 2 weeks.

          -  Active malignancy other than breast cancer, in situ carcinoma of the cervix,
             controlled resected thyroid well differentiated carcinoma or non-melanomatous skin
             cancer in the past 5 years

          -  Active cardiovascular disease such as angina, ventricular tachycardia, uncontrolled
             hypertension

          -  Active uncontrolled infection

          -  Symptomatic brain metastases

          -  Lymphangitic carcinomatosis involving >50% of the lungs

          -  Evidence of metastases involving more than one third of the liver on sonogram or CT

          -  Patients not able or unwilling to give informed consent
Clinical trial NCT02345044 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: cs-3150, placebo, eplerenone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Subjects with essential hypertension (Sitting SBP ≥ 140 mmHg and < 180 mmHg, Sitting
             DBP ≥ 90 mmHg and < 110 mmHg,and 24h-hr blood pressure more than 130 mmHg in SBP and
             80 mmHg in DBP)

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetes mellitus with albuminuria

          -  Serum potassium level < 3.5 or ≥ 5.1 mEq/L

          -  Reversed day-night life cycle including overnight workers

          -  eGFR < 60 mL/min/1.73 m^2
Clinical trial NCT02345057 (phase 2, status: completed)
Conditions: diabetic nephropathy
ICD codes: E10.21, E11.21, E13.21, E08.21, E09.21
Drugs: cs-3150, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus

          -  Male or female subjects aged 20 years or older at informed consent

          -  Subjects with urinary albumin to creatine ratio (UACR) ≥ 45 mg/g Cr and < 300 mg/g Cr

          -  Estimated glomerular filtration rate by creatinine (eGFRcreat) ≥ 30 mL/min/1.73 m^2

          -  Subjects treated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
             receptor blocker (ARB) for at least 3 months prior to treatment period

        Exclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c (NGSP) >=8.4%

          -  Secondary glucose intolerance

          -  Subjects diagnosed with non-diabetic nephropathy

          -  Nephrotic syndrome

          -  Secondary hypertension or malignant hypertension

          -  Serum potassium level in any of the following categories: For subjects with eGFRcreat
             of ≥ 45 mL/min/1.73 m^2, serum potassium level of < 3.5 mEq/L or ≥ 5.1 mEq/L; For
             subjects with eGFRcreat of ≥ 30 mL/min/1.73 m^2 and < 45 mL/min/1.73 m^2, serum
             potassium level of < 3.5 mEq/L or ≥ 4.8 mEq/L
Clinical trial NCT02345070 (phase 2, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: sar156597, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria :

          -  Adult male or female participants.

          -  Documented diagnosis of IPF according to the current 2011 American Thoracic
             Society/European Respiratory Society/Japanese Respiratory Society/ American Latin
             Thoracic Association (ATS/ERS/JRS/ALAT) guidelines.

          -  Signed written informed consent.

        Exclusion criteria:

          -  Age less than or equal to 40 years.

          -  IPF disease diagnosis greater than 5 years.

          -  Forced vital capacity (FVC) less than (<) 40 percent (%) of predicted value.

          -  Carbon monoxide diffusing lung capacity (DLCO) corrected for hemoglobin <30% of
             predicted value.

          -  Severe chronic obstructive bronchitis as characterized by forced expiratory volume in
             1 second /forced vital capacity (FEV1/FVC) <0.70.

          -  Need for 24 hours of oxygen therapy or oxygen saturation <88% after 10 minutes
             breathing ambient air at rest.

          -  Known diagnosis of significant respiratory disorders other than IPF.

          -  Pulmonary artery hypertension requiring a specific treatment.

          -  Currently listed and/or anticipated for lung transplantation within the next 6 months
             (on an active list).

          -  History of vasculitis or connective tissue disorders.

          -  Known human immunodeficiency virus or chronic viral hepatitis.

          -  Participants with active tuberculosis or incompletely treated latent tuberculosis
             infection.

          -  Use of any cytotoxic/immunosuppressive agent including but not limited to
             azathioprine, cyclophosphamide, methotrexate, and cyclosporine within 4 weeks prior to
             screening.

          -  Use of any cytokine modulators (etanercept, adalimumab, efalizumab, infliximab,
             golimumab, certolizumab, rituximab) within 12 weeks or 5 half-lives of screening (24
             weeks for rituximab and 24 months for alefacept).

          -  Use of any investigational drug within 1 month of screening, or 5 half-lives, if known
             ( whichever was longer), or within 12 weeks for stem cell therapy.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02346578 (phase 2, status: completed)
Conditions: castration-resistant prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzalutamide, flutamide
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Testosterone of less than 50 ng/dL

          -  Participants who was detected of disease progression on image or relapse of PSA (All
             PSA values measured 3 time at least one week interval are consecutively increased and
             final value is 2 ng/mL or more. If third value is not higher than second one, fourth
             measurement will be undertaken and its value must be higher than second one.)

          -  Participants who relapsed after CAB with bicalutamide

          -  Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1

          -  Aged 20 years or older

          -  Participants who provided written informed consent

        Exclusion Criteria:

          -  Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except
             for neoadjuvant therapy

          -  With active double cancer

          -  Any prior treatment with bicalutamide within 6 weeks

          -  Participants who received systemic biological therapy (except for existing approved
             drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue)
             or received treatment with other antitumor agent for prostate cancer

          -  With serious complication

          -  History of hypersensitivity to enzalutamide or any other excipient of enzalutamide

          -  History of hypersensitivity to flutamide-containing agent

          -  With liver dysfunction

          -  Participants who are considered as inadequate by the investigator
Clinical trial NCT02348281 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bicalutamide
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
Reason stopped: 
    it's too slow to enroll suitable patients into this study
  
Eligibility criteria:

        Inclusion Criteria:

          1. Females elder than 18

          2. Histological proven unresectable or metastatic breast cancer patients who underwent at
             least one chemotherapy regimen for metastatic disease

          3. Patients with androgen Receptor (AR) positive (IHC >10% nuclear staining) either for
             primary tumor or metastatic lesion

          4. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human
             epithelial receptor-2 (HER2) by IHC (ER <1%, PR <1% and Her2 negative). A negative
             Her2 gene amplification should be verified by FISH test for those patients with Her2
             (2+). For those with Her2 (1+), FISH test might be considered by the investigator.

          5. At least one measurable disease according to the response evaluation criteria in solid
             tumor (RECIST 1.1)

          6. Performance status no more than 2

          7. All patients enrolled are required to have adequate hematologic, hepatic, and renal
             function

          8. Life expectancy longer than 12 weeks

          9. No serious medical history of heart, lung, liver and kidney

         10. Be able to understand the study procedures and sign informed consent.

         11. Patients with good compliance

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection
             during the process of the study

          3. Patients treated with an investigational product within 4 weeks before the enrollment

          4. Patients who received chemotherapy within 4 weeks before the enrollment

          5. Patients with symptomatic central nervous system metastases are not permitted, except
             for those with stable and asymptomatic brain metastases who have completed cranial
             irradiation, and have at least one measurable lesion outside the brain. Radiotherapy
             should be completed within 4 weeks prior to the registration

          6. Other active malignancies (including other hematologic malignancies) or other
             malignancies within the last 5 years, except for cured nonmelanoma skin cancer or
             cervical intraepithelial neoplasia.

          7. Patients having a history of clinically significant cardiovascular, hepatic,
             respiratory or renal diseases, clinically significant hematological and endocrinal
             abnormalities, clinically significant neurological or psychiatric conditions

          8. Uncontrolled serious infection
Clinical trial NCT02348359 (phase 2, status: terminated)
Conditions: age-related macular degeneration (amd), macular degeneration, exudative age-related macular degeneration, amd, macular degeneration, age-related, 10, eye diseases, retinal degeneration, retinal diseases
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230, H35.3230, H35.3210, H35.3220, H35.3233, H35.3290, H35.3213, H35.3223
Drugs: x-82, anti-vegf, placebo
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    interim analysis found study had achieved primary objective
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in
             one or both eyes for at least 6 months prior to joining the study and has required at
             least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater
             than 6 weeks for the past two injections in the eye that is selected to be the study
             eye.

          -  Must have demonstrated a reduction in macular fluid or macular thickness in the study
             eye 14 days following an anti-VEGF injection at Screening Visit 1

          -  Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25
             letters (20/320) or better in both eyes

        Exclusion Criteria:

          -  Previous vitrectomy to the study eye within 30 days of Screening Visit 1

          -  Choroidal neovascularization (CNV) due to causes other than AMD

          -  Proliferative diabetic retinopathy in either eye
Clinical trial NCT02349516 (phase 2, status: withdrawn)
Conditions: diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: squalamine lactate ophthalmic solution 0.2%
SMILES: CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O
Reason stopped: 
    study cancelled as of 9/12/15. 0 subjects enrolled.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will have clinically significant diabetic macular edema of ≥ 300 microns with
             central involvement using the Heidelberg or Cirrus machine

          -  Best corrected visual acuity of 20/32 to 20/320 inclusive in the study eye

          -  Adults ≥ 18 years of age with type 1 or 2 diabetes mellitus with diabetic macular
             edema

        Exclusion Criteria:

          -  History of vitreoretinal surgery in the study eye

          -  Panretinal laser photocoagulation or macular laser photocoagulation in the study eye
             within 3 months of screening

          -  Any prior laser in study eye

          -  Previous use of intraocular or periocular corticosteroids in the study eye within 6
             months of screening

          -  Previous treatment with anti-angiogenic drugs in either eye within 3 months of
             screening

          -  Uncontrolled diabetes mellitus with HbA1c levels greater than 12

          -  Ocular disorders in the study eye, other than diabetic macular edema, that my confound
             interpretation of study results